Back to Atlas
BSemi-durableStandard research/education caution
CMP-0186
Research/Regional
Crystagen
Immune / Longevity
Immune and aging-support positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Short peptide bioregulator
- Primary mechanism
- Peptide bioregulation
- Primary market use
- Immune/longevity
Pharmacology
- Molecular weight (Da)
- ~390
- Oral bioavailability
- Unknown
- Half-life
- Plasma t1/2 class estimate ~0.5–2 h; aftereffect 1.5–2 months
- Route tags
- SubQ; IM
- Evidence level
- Limited human/Regional
- Clinical status
- Research/Regional
- Value-for-money score
- 4 / 10
Reported protocol signal
Common reported Cytogen injectable protocol: 1–10 mg daily for 10–20 days SQ/IM; popular simplified protocol 2 mg daily for 20–30 days, 1 month on / 2 months off, 2–3×/year.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Evidence base limited